If the Ryan Haight Act's in-person examination requirement fully reinstates for new controlled substance prescriptions via telehealth, what does that actually mean in practice? It's less disruptive than it sounds — but it changes the onboarding process for men starting TRT for the first time.
What the In-Person Requirement Actually Entails
The Ryan Haight Act doesn't require that every telehealth visit for controlled substances be in-person. It requires that the prescriber conduct at least one in-person medical evaluation before issuing the first controlled substance prescription via telemedicine. After that initial evaluation, ongoing management can continue via telehealth.
In practical terms:
- You'd need to see a prescriber face-to-face once — before your first testosterone prescription
- That prescriber could be the telehealth platform's clinician (if they have a physical location you can visit) or a local physician who conducts the exam and communicates with the telehealth prescriber
- After the in-person evaluation is documented, subsequent prescriptions, dose adjustments, and monitoring could continue via telehealth
How Platforms Are Preparing
The Partner Clinic Model
Several telehealth TRT platforms are establishing partnerships with brick-and-mortar clinical networks. The patient completes an in-person evaluation at a partner clinic, the partner clinic documents the encounter and shares records with the telehealth platform, and the telehealth platform takes over ongoing management. This model preserves the convenience of telehealth for 95% of the patient experience while satisfying the in-person requirement for the initial encounter.
The Lab-Visit Hybrid
Some platforms are exploring whether an in-person blood draw at a lab facility (Quest, LabCorp, or partner phlebotomy location) combined with a video consultation could satisfy a modified in-person requirement. This interpretation is legally uncertain but would be the least disruptive approach if accepted.
The Mobile Provider Model
Emerging platforms are sending clinicians to patients' homes or local facilities for the initial evaluation. This "house call" approach is more expensive per patient but eliminates the geographic barrier of requiring patients to travel to a specific clinic location.
What It Means for You
If You're Starting TRT After Potential Rule Changes
- Expect one in-person visit during onboarding — likely at a partner clinic or lab facility near you
- The visit will include a physical examination, medical history review, and initial lab orders
- After the in-person evaluation, your ongoing TRT management returns to telehealth
- Cost may include a one-time exam fee ($100–$250) in addition to the platform's standard subscription
- Geographic access becomes a consideration — men in very rural areas may face longer travel to a partner clinic
The Bottom Line
One Visit, Not a Return to the Old Model
Even if the in-person requirement returns for new patients, it's a single evaluation — not a permanent shift back to office-based care. The vast majority of TRT management will continue via telehealth. The platforms that prepare partnerships and hybrid models now will offer the smoothest onboarding experience for new patients under any new rules.